Search bioRxivSearch

Biology subjects

Hernandez-Vargas, E.

Publications and source records attributed to Hernandez-Vargas, E..

2 recordsLinked to original sources

The 2017 plague outbreak in Madagascar: data descriptions and epidemic modelling

From August to November 2017, Madagascar endured an outbreak of plague. A total of 2417 cases of plague were confirmed, causing a death toll of 209. Public health intervention efforts were introduced and successfully stopped the epidemic at the end of November. The plague, however, is endemic in the region and occurs annually, posing the risk of future outbreaks. To understand on the plague transmission, we collected real-time data from official reports, described the outbreaks characteristics, and estimated transmission parameters using statistical and mathematical models. The pneumonic plague epidemic curve exhibited multiple peaks, coinciding with sporadic introductions of new bubonic cases. Optimal climate conditions for rat flea to flourish were observed during the epidemic. Estimate of the plague basic reproduction number during the large wave of the epidemic was high, ranging from 5-7 depending on model assumptions. The incubation and infection period for bubonic and pneumonic plague were 4.3 and 3.4 days and 3.8 and 2.9, respectively. Parameter estimation suggested that even with a small fraction of the population exposed to infected rat fleas (1/10000) and a small probability of transition from a bubonic case to a secondary pneumonic case (3%), the high human-to-human transmission rate can still generate a large outbreak. Controlling rodent and fleas can prevent new index cases, but managing human-to-human transmission is key to prevent large-scale outbreaks.

epidemiology

Neuraminidase inhibitors - is it time to call it a day?

Stockpiling neuraminidase inhibitors (NAIs) such as oseltamivir and zanamivir is part of a global effort to be prepared for an influenza pandemic. However, the contribution of NAIs for treatment and prevention of influenza and its complications is largely debatable. Here, we developed a transparent mathematical modelling setting to analyse the impact of NAIs on influenza disease at within-host and population level. Analytical and simulation results indicate that even assuming unrealistically high efficacies for NAIs, drug intake starting on the onset of symptoms has a negligible effect on an individual's viral load and symptoms score. Increasing NAIs doses does not provide a better outcome as is generally believed. Considering Tamiflu's pandemic regimen for prophylaxis, different multiscale simulation scenarios reveal modest reductions in epidemic size despite high investments in stockpiling. Our results question the use of NAIs in general to treat influenza as well as the respective stockpiling by regulatory authorities.

systems biology